Next Article in Journal
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
Previous Article in Journal
DLEC1 Expression Is Modulated by Epigenetic Modifications in Hepatocelluar Carcinoma Cells: Role of HBx Genotypes
Previous Article in Special Issue
A Quest for Initiating Cells of Head and Neck Cancer and Their Treatment
Cancers 2010, 2(3), 1705-1716; doi:10.3390/cancers2031705

Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer

* ,
Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston SC 29425 USA
* Author to whom correspondence should be addressed.
Received: 28 August 2010 / Accepted: 14 September 2010 / Published: 16 September 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
View Full-Text   |   Download PDF [269 KB, uploaded 16 September 2010]   |  


Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer.
Keywords: aberrant crypt foci; biomarker; colon cancer; chemoprevention aberrant crypt foci; biomarker; colon cancer; chemoprevention
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Wargovich, M.J.; Brown, V.R.; Morris, J. Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer. Cancers 2010, 2, 1705-1716.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert